Center for Immunotherapy and Cell-Based Technologies

Novosibirsk — Kaliningrad — Moscow — Irkutsk
Main

Astrocytoma

Xenovaccinotherapy for cancer

http://www.medicalnewstoday.com/rss/cancer-oncology.xmlhttp://www.medicalnewstoday.com/rss/immune_system.xmlhttp://www.medicalnewstoday.com/rss/multiple_sclerosis.xmlhttp://www.medicalnewstoday.com/rss/stem_cell_research.xml

09.07.2011 Novartis Pharmaceuticals Corporation ("Novartis") announced Phase III trial results that showed more than one-third of patients taking Afinitor® (ever...

16.03.2011 Pilocytic astrocytoma, the most common brain tumor in children, is usually slow-growing and benign. However, surgeons often cannot completely remove t...


Immunotherapy for cancer

An active specific immunotherapy (vaccinotherapy) is a strategy using tumor-associated antigens for including antitumor immune responses. The small structural distinctions of the xenogenic tumor-associated antigens from their human analogues render these antigens highly immunogenic and capable of including immune-mediated, antitumor responses in a patient not only at early, but also at advanced stages of disease, when tumor-derived immunosuppression is significant. Tumor-specfic immunotherapy is able to generate a selective and long-term antitumor effect. Such a therapy has no complications attributable to chemotherapy.

Xenovaccinotherapy for cancer